US-based startup Heranova Lifesciences Holdingce in China as well, has announced the successful completion of a $ 13.5 million seed and seed+ financing to develop and offer integrated women's health solutions worldwide.

This funding will be used to launch a serial of non-invasive endometriosis tests and advance two innovative (non-hormonal and non-antibiotic) therapeutic programmes for endometriosis and bacterial vaginosis. 

The company is also actively seeking global or regional partnerships for other women's health indications. Institutional investors such as Pivotal bioVenture Partners China, Sinovation Ventures, Emerging Technology Partners, and Triwise Capital participated in this round.

The company was founded in 2022 by a team of serial entrepreneurs and seasoned MNC executives with support from a world-class Scientific Advisory Board. Heranova has already established presences in the United States and Asia.

According to Dr Farideh Bischoff, the Chief Diagnostic Medical Officer at Heranova, "The diagnostic products developed by our R&D team have received endorsement from global leading KOLs as they may help to significantly shorten the time from disease onset to diagnosis and subsequent treatment. To provide an integrated solution, we are also developing first-in-class, non-hormonal therapeutic programmes for endometriosis."